Natalie C. Holles - 19 May 2026 Form 4 Insider Report for Aura Biosciences, Inc. (AURA)

Reporting relationship: Chief Executive Officer and President, Director
Issuer ticker: AURA
Reported as of: 19 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 May 2026, 16:59:48 UTC
Prior SEC filing: 07 May 2026
Next SEC filing: 24 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Conor Kilroy, as Attorney-in-Fact

Key filing fact

Natalie C. Holles filed Form 4 for Aura Biosciences, Inc. (AURA) on 19 May 2026.

Key facts

This page summarizes Natalie C. Holles's Form 4 filing for Aura Biosciences, Inc. (AURA).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 May 2026, 16:59.

Change

Previous filing in this sequence was filed on 07 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001580111 Primary reporting owner

Holles Natalie C.

Relationship: Chief Executive Officer and President, Director
Address: C/O AURA BIOSCIENCES, INC., 80 GUEST STREET, BOSTON
Signature: /s/ Conor Kilroy, as Attorney-in-Fact
Signature date: 19 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AURA transaction

Common Stock

Award

Transaction value
Shares: +600,118
Change %
Price: $0.000000^*
Shares after: 600,118
Date: 19 May 2026
Ownership: Direct
Footnotes: F1

AURA transaction

Common Stock

Award

Transaction value
Shares: +553,844
Change %: +92%
Price: $0.000000^*
Shares after: 1,153,962
Date: 19 May 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AURA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +2,169,103
Change %
Price: $0.000000^*
Shares after: 2,169,103
Date: 19 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,169,103
Exercise price: $7.39
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These shares were acquired pursuant to a restricted stock unit ("RSU") award as Inducement Awards. Each RSU represents the right to receive one share of the Issuer's common stock. These RSUs vest in four substantially equal annual installments beginning on April 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.

Footnote F2

These shares were acquired pursuant to a performance RSU ("PRSU") award as Inducement Awards. The PRSUs are subject to both time-based vesting and the achievement of a performance condition, both of which must be satisfied before the PRSUs will be deemed vested. The PRSUs shall vest in four substantially equal annual installments commencing on April 15, 2027, subject to Ms. Holles' continued service as of each such time-based vesting date and the satisfaction of the performance condition. The expiration date of the PRSUs is the earlier of (i) the sixth (6th) anniversary of the grant date and (ii) the date Ms. Holles no longer has a service relationship with the Issuer. Any such PRSUs that have not vested on or prior to such expiration date shall be forfeited for no consideration.

Footnote F3

The shares underlying this option vest as follows: 25% of the shares vest on April 30, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

SEC remarks

Chief Executive Officer and President